Lama Mohammed Albelowi

Dr. Lama Mohammed Albelowi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2020 in Cureus
Verified
Journal Article
Open access
PDF file
MZMohammed Zolaly
Mohammed Zolaly
FZFarah M. Zolaly
Farah M. Zolaly
LALama Mohammed Albelowi
Lama Mohammed Albelowi
RSRaafat Shuqdar
Raafat Shuqdar
MBMohammed A Al Belowi
Mohammed A Al Belowi
MAMuayad Albadrani
Muayad Albadrani
Beta thalassemia major (BTM) is a chronic hereditary blood disorder. Patients are dependent on blood transfusion and are prone to multiple comorbidities. Depression, anxiety, and stress (DAS) can complicate their condition. No reports from Saudi Arabia to measure DAS in BTM patients. We report the prevalence of DAS symptoms in our BTM patients using the DASS-21 (Depression, Anxiety, and Stress Scale - 21 Items) test. A cross-sectional study including adolescents and adults aged 14 years and above with BTM treated in Almadinah Almunawwarah and excluding patients who had bone marrow transplant or with central nervous system insults were performed. A total of 31 male and 31 female patients were enrolled, with a mean age of 24.32 ± 7.05 years. Depression symptoms were detected in 60 % of patients, anxiety symptoms were detected in half of the studied group, and stress symptoms were detected in 38.7% of patients. We found a significant positive correlation between DAS and DASS total score. Age below or above 18, parent’s employment, patient’s educational level, and status of satisfaction about medical care were statistically significant in having positive effects on scores of DAS symptoms. BTM patients are prone to develop psychological disorders, which can affect the course of the disease. Our results are comparable to international and Arab population studies, which have the highest reported prevalence. It is important to not ignore the psychological evaluation of patients with BTM and to refer them for proper evaluation and management.

17 December 2025 in Reports
Verified
Journal Article
Open access
PDF file
FAFawwaz freih Alshammrie
Fawwaz freih Alshammrie
LALama Zaid Alhemshy
Lama Zaid Alhemshy
MAMaitha Mohammed Althawy
Maitha Mohammed Althawy
MAMaryam Mohammad Alfaraj
Maryam Mohammad Alfaraj
AAAseel Saleh Alotaibi
Aseel Saleh Alotaibi
LALama Mohammed Albelowi
Lama Mohammed Albelowi
Background: Recent advancements in regenerative medicine have introduced mesenchymal stem cell–derived exosomes (MSC-Exos) as a novel therapeutic approach. Exosomes are extracellular vesicles containing proteins, lipids, and RNAs capable of modulating cellular behavior and promoting tissue regeneration. A systematic review of human studies is warranted to summarize outcomes, assess therapeutic value, and guide clinical applications. Objectives: This systematic review synthesizes current evidence on mesenchymal stem cell–derived exosomes for cutaneous scars, aging, and hyperpigmentation, with a focus on functional and aesthetic outcomes. Method: A comprehensive search of PubMed, Scopus, Embase, Web of Science, and Google Scholar (January 2010–July 2025) was performed following 2020 PRISMA guidelines. Eligible studies included studies that were randomized controlled trials, pilot studies, case series, and case reports involving human participants treated with MSC-Exos. Outcomes assessed were scar remodeling, pigmentation, skin regeneration, recurrence, and adverse events. Data extraction and bias assessment were conducted independently. Result: Six studies (n = 99; age 19–72 years) from diverse regions, including the United States, the Republic of Korea, and México, were included. MSC-Exos therapy showed promising improvements in reducing scar thickness (32.5% vs. 19.9%, p < 0.01), wrinkle parameters were reduced by 1 (2.4–14.4% vs. 6.6–7.1%, p < 0.05), and elasticity was enhanced (+11.3% vs. −3.3%, p = 0.002) Additional benefits included hydration (+6.5% vs. +4.5%, p = 0.37) and reduced melanin index (−9.9% vs. −1%, p = 0.44). The Global Aesthetic Improvement Scale score showed significant improvement (p = 0.005). Using the Investigator Global Assessment, 16 out of 25 areas treated with exosomes showed significant improvement (grade ≥ 2), compared to 12 out of 25 areas in the control group (p = 0.02), indicating that exosome treatment led to more visible improvement. Complete resolution of icepick scars, partial improvement of boxcar/rolling scars, and no recurrence of keloids (18/21) were reported. Adverse events were mild and transient. Conclusions: Early human evidence suggests that MSC-Exos may offer potential therapeutic benefits for scars, hyperpigmentation, and skin aging, with favorable short-term safety profiles. However, the current evidence remains preliminary due to small sample sizes, heterogeneous study designs, and limited follow-up durations. Larger, well-designed randomized trials are needed to confirm long-term efficacy and safety.

1 January 2026 in Dermatology Research and Practice
Verified
Journal Article
Open access
NRNouf Bin Rubaian
Nouf Bin Rubaian
FAFawzeyah Alnakhli
Fawzeyah Alnakhli
LALama Mohammed Albelowi
Lama Mohammed Albelowi
AAAsrar Alharbi
Asrar Alharbi
DADanah Alnajjar
Danah Alnajjar
DADeemah AlHuraish
Deemah AlHuraish
Objective: The appearance of our physical features, including our hair, holds great significance in our lives. Shampooing is a widely adopted practice for improving hair condition. However, there is an ongoing debate regarding the impact of shampooing frequency on hair and scalp health. This study aimed to investigate the relationship between the frequency of hair shampooing and the condition of both hair and scalp. Methods: A cross‐sectional study design was employed to gather data through online survey questionnaires administered in Arabic and targeted at Saudi Arabian citizens. The study included a sample size of 4796 participants from various clinics across Saudi Arabia. Descriptive statistics were utilized to analyze the data, calculating frequencies and percentages for different groups. Chi‐square tests and inferential analysis were conducted to determine the association between variables. Results: The study identified a significant correlation between hair type and hair problems. Long hair and hairstyles with curls were associated with higher rates of hair breakage and daily hair loss. The findings demonstrated that the frequency of hair shampooing directly influenced the condition of both hair and scalp. Increased shampooing frequency was found to improve hair and scalp conditions. Conclusion: In conclusion, this study establishes that a higher frequency of shampooing enhances the condition of both hair and scalp. Therefore, we recommend that individuals aiming to enhance their physical appearance should consider increasing the frequency of shampoo usage.

1 June 2026 in Saudi Medical Horizons Journal
Verified
Journal Article
Open access
LALama Mohammed Albelowi
Lama Mohammed Albelowi
GEGhaidaa Elmehallawy
Ghaidaa Elmehallawy
AAAli Amer M. Alghamdi
Ali Amer M. Alghamdi
HAHassan Ali Alzubaidi
Hassan Ali Alzubaidi
HAHamza M. Alayoubi
Hamza M. Alayoubi
RDRanda E. Dafaalla
Randa E. Dafaalla
Janus kinase (JAK) inhibitors have emerged as a groundbreaking option in dermatologic therapy, offering a more precise approach to manage inflammatory and autoimmune skin diseases. This narrative review explores the use of JAK inhibitors in three key conditions: atopic dermatitis, alopecia areata, and vitiligo. These disorders share a common underlying mechanism involving disruption of the JAK-STAT signaling pathway, which contributes to abnormal immune responses. A growing body of clinical research highlights the effectiveness of both topical and oral JAK inhibitors in managing symptoms across these conditions. For instance, ruxolitinib cream and oral agents such as abrocitinib, baricitinib, and upadacitinib have shown strong anti-inflammatory effects and relief of itching in atopic dermatitis. In the treatment of alopecia areata, medications like baricitinib, ritlecitinib, and the recently approved deuruxolitinib have brought renewed optimism for individuals with more severe forms of the disease. Meanwhile, topical ruxolitinib has shown promise in restoring pigment, particularly on facial areas affected by vitiligo. Although these therapies are generally well-tolerated, potential risks such as infections and cardiovascular concerns necessitate ongoing safety monitoring. Overall, this review brings together the latest evidence on the use of JAK inhibitors in dermatology, highlighting their clinical impact and underscoring the need for continued research to optimize long-term safety and patient selection.